BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Phase 2
Terminated
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 21
- Registration Number
- NCT02170025
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT02168777
RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Drug: Roniciclib (BAY1000394)Drug: Placebo
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 142
- Registration Number
- NCT02161419
Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Riociguat(Adempas,BAY63-2521)
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 48
- Registration Number
- NCT02159313
Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women
Phase 1
Completed
- Conditions
- Drug Interactions
- Interventions
- Drug: MicrogynonDrug: Riociguat (Adempas,BAY63-2521)
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 31
- Registration Number
- NCT02159326
Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
Completed
- Conditions
- Contraception
- Interventions
- Drug: BAY98-7071_EE20/DRSP/L-5-MTHF
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1500
- Registration Number
- NCT02159261
Copanlisib Pharmacodynamic Study
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT02155582
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1474
- Registration Number
- NCT02141438
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT02138812
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
Phase 2
Terminated
- Conditions
- Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 147
- Registration Number
- NCT02138825
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Via Christi Clinic, Wichita, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath